{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:48:12Z","timestamp":1793411292085,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.soc.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:20:56Z","timestamp":1655248856000},"page":"527-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Leiomyosarcoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Nicolas","family":"Devaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Vornicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korosh","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Demicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mitric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus Q.","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Gladdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.soc.2022.03.011_bib1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","article-title":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative RPS working group","volume":"263","author":"Gronchi","year":"2016","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.soc.2022.03.011_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.hoc.2013.07.002","article-title":"Leiomyosarcoma","volume":"27","author":"Serrano","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.soc.2022.03.011_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","article-title":"Soft tissue and uterine leiomyosarcoma","volume":"36","author":"George","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jso.2930280307","article-title":"Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases","volume":"28","author":"Hashimoto","year":"1985","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.soc.2022.03.011_bib5","unstructured":"Cancer IAfRo, editor. WHO classification of tumours of soft tissue and bone. 5 edition. Lyon (France)2020."},{"key":"10.1016\/j.soc.2022.03.011_bib6","first-page":"1","article-title":"Soft tissue sarcoma. Epidemiology and prognosis in 508 patients","volume":"259","author":"Gustafson","year":"1994","journal-title":"Acta Orthop Scand Suppl"},{"issue":"12","key":"10.1016\/j.soc.2022.03.011_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(09)70226-8","article-title":"Clinical management of uterine sarcomas","volume":"10","author":"Amant","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/jso.20970","article-title":"Gastrointestinal stromal tumors and leiomyosarcomas","volume":"97","author":"Katz","year":"2008","journal-title":"J\u00a0Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.011_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncr.22395","article-title":"Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group","volume":"109","author":"Svarvar","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.soc.2022.03.011_bib10","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/1097-0142(19841115)54:10<2147::AID-CNCR2820541015>3.0.CO;2-9","article-title":"Leiomyosarcomas of venous origin in the extremities. A correlated clinical, roentgenologic, and morphologic study with diagnostic and surgical implications","volume":"54","author":"Berlin","year":"1984","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10434-001-0290-3","article-title":"Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison","volume":"8","author":"Clary","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.03.011_bib12","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1245\/s10434-013-2876-y","article-title":"Predictors of survival and recurrence in primary leiomyosarcoma","volume":"20","author":"Gladdy","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00000658-199301000-00012","article-title":"Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients","volume":"217","author":"Fong","year":"1993","journal-title":"Ann Surg"},{"issue":"35","key":"10.1016\/j.soc.2022.03.011_bib14","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1200\/JCO.19.01096","article-title":"Bone and soft-tissue sarcoma risk in long-term survivors of hereditary retinoblastoma treated with radiation","volume":"37","author":"Kleinerman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijc.2910330108","article-title":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system","volume":"33","author":"Trojani","year":"1984","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib16","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1038\/s41467-021-24677-6","article-title":"Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival","volume":"12","author":"Anderson","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.soc.2022.03.011_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/onc.2009.381","article-title":"Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling","volume":"29","author":"Beck","year":"2010","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.soc.2022.03.011_bib20","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1541-7786.MCR-20-0197","article-title":"Oncogenic gene-expression programs in leiomyosarcoma and characterization of conventional, inflammatory, and uterogenic subtypes","volume":"18","author":"Hemming","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.soc.2022.03.011_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yasu.2015.04.002","article-title":"Principles in management of soft tissue sarcoma","volume":"49","author":"Crago","year":"2015","journal-title":"Adv Surg"},{"issue":"961","key":"10.1016\/j.soc.2022.03.011_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/18595145","article-title":"Radiological imaging features of non-uterine leiomyosarcoma","volume":"81","author":"O'Sullivan","year":"2008","journal-title":"Br J Radiol"},{"issue":"8","key":"10.1016\/j.soc.2022.03.011_bib23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.2967\/jnumed.109.074229","article-title":"Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET","volume":"51","author":"Benz","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.soc.2022.03.011_bib24","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ejso.2017.06.009","article-title":"Needle tract seeding following core biopsies in retroperitoneal sarcoma","volume":"43","author":"Van Houdt","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"13","key":"10.1016\/j.soc.2022.03.011_bib25","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1245\/s10434-019-07656-6","article-title":"Early and late complications of percutaneous core needle biopsy of retroperitoneal tumors at two tertiary sarcoma centers","volume":"26","author":"Berger-Richardson","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2022.03.011_bib26","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1245\/s10434-021-09654-z","article-title":"Management of primary retroperitoneal sarcoma (RPS) in the adult: an updated consensus approach from the Transatlantic Australasian RPS Working Group","volume":"28","author":"Swallow","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.011_bib27","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/cncr.33323","article-title":"Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: a multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group","volume":"127","author":"Tseng","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2022.03.011_bib28","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"D'Ambrosio","year":"2020","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.soc.2022.03.011_bib29","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.011_bib30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1245\/s10434-011-1954-2","article-title":"Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava","volume":"19","author":"Fiore","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.03.011_bib31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1245\/s10434-010-1057-5","article-title":"Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control","volume":"17","author":"Bonvalot","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2008.17.8871","article-title":"Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients","volume":"27","author":"Gronchi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.011_bib33","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/SLA.0000000000002250","article-title":"Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group","volume":"267","author":"MacNeill","year":"2018","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jvsv.2018.10.023","article-title":"Outcome of iliocaval resection and reconstruction for retroperitoneal sarcoma","volume":"7","author":"Ferraris","year":"2019","journal-title":"J\u00a0Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.soc.2022.03.011_bib35","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/EDBK_200573","article-title":"Multidisciplinary management of oligometastatic soft tissue sarcoma","volume":"38","author":"Grilley-Olson","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/jso.25115","article-title":"Impact of surgery in patients with metastatic soft tissue sarcoma: a monocentric retrospective analysis","volume":"118","author":"Wigge","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/SLA.0000000000001149","article-title":"Histology-based classification predicts pattern of recurrence and improves risk stratification in primary retroperitoneal sarcoma","volume":"263","author":"Tan","year":"2016","journal-title":"Ann Surg"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2022.03.011_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ijgo.12613","article-title":"Uterine sarcomas","volume":"143","author":"Mbatani","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2017.02.019","article-title":"Uterine leiomyosarcoma: epidemiology, contemporary treatment strategies and the impact of uterine morcellation","volume":"145","author":"Ricci","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.soc.2022.03.011_bib40","unstructured":"Martee L Hensley MML. Treatment and Prognosis of Uterine Leiomyosarcoma. UptoDate [Internet]. 2021."},{"key":"10.1016\/j.soc.2022.03.011_bib41","unstructured":"Stewart EA. Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas. UptoDate [Internet]. 2021."},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jmig.2016.01.022","article-title":"The role of endometrial biopsy in the preoperative detection of uterine leiomyosarcoma","volume":"23","author":"Hinchcliff","year":"2016","journal-title":"J\u00a0Minim Invasive Gynecol"},{"key":"10.1016\/j.soc.2022.03.011_bib43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejogrb.2019.03.017","article-title":"A\u00a0more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes' results in patients with uterine masses","volume":"236","author":"Di Cello","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.soc.2022.03.011_bib44","unstructured":"National Comprehensive Cancer Network. Uterine Neoplasms. 2021. In: NCCN Clinical Practice Guidelines in Oncology [Internet]."},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2014.11.011","article-title":"Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis","volume":"137","author":"Bogani","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib46","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jmig.2016.02.001","article-title":"Peritoneal washings after power morcellation in laparoscopic myomectomy: a pilot study","volume":"23","author":"Toubia","year":"2016","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.011_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jog.14171","article-title":"Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: a Korean multicenter study","volume":"46","author":"Kim","year":"2020","journal-title":"J\u00a0Obstet Gynaecol Res"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","article-title":"Prognosis and treatment of uterine leiomyosarcoma: a National Cancer Database study","volume":"145","author":"Seagle","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.011_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ygyno.2019.05.015","article-title":"Secondary surgical resection for patients with recurrent uterine leiomyosarcoma","volume":"154","author":"Cybulska","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ygyno.2020.12.032","article-title":"Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: a systematic review of literature","volume":"161","author":"Matsuzaki","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"1s","key":"10.1016\/j.soc.2022.03.011_bib51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/fon-2016-0499","article-title":"Treatment of soft tissue sarcoma: a focus on earlier stages","volume":"13","author":"Gronchi","year":"2017","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.soc.2022.03.011_bib52","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.011_bib53","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"9092","key":"10.1016\/j.soc.2022.03.011_bib54","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(97)08165-8","article-title":"Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data","volume":"350","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A\u00a0systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.soc.2022.03.011_bib56","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/annonc\/mdu460","article-title":"Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials","volume":"25","author":"Le Cesne","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.soc.2022.03.011_bib57","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.6004\/jnccn.2020.0058","article-title":"NCCN guidelines insights: soft tissue sarcoma, version 1.2021","volume":"18","author":"von Mehren","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib58","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.1999.17.1.150","volume":"17","author":"Van Glabbeke","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","article-title":"Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study","volume":"15","author":"Savina","year":"2017","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.soc.2022.03.011_bib61","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.soc.2022.03.011_bib62","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.03.011_bib63","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.soc.2022.03.011_bib65","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1634\/theoncologist.2011-0467","volume":"17","author":"Pautier","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.soc.2022.03.011_bib66","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.soc.2022.03.011_bib67","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.32117","article-title":"Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"issue":"10028","key":"10.1016\/j.soc.2022.03.011_bib68","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.soc.2022.03.011_bib69","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib70","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ygyno.2004.11.036","article-title":"Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study","volume":"96","author":"Sutton","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"9829","key":"10.1016\/j.soc.2022.03.011_bib71","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.011_bib73","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib74","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.10.064","article-title":"Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors","volume":"116","author":"O'Cearbhaill","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.soc.2022.03.011_bib75","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study","volume":"123","author":"Ben-Ami","year":"2017","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.soc.2022.03.011_bib76","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.soc.2022.03.011_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071873","article-title":"A\u00a0retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas","volume":"12","author":"Monga","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.soc.2022.03.011_bib78","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7791","key":"10.1016\/j.soc.2022.03.011_bib79","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B\u00a0cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.soc.2022.03.011_bib80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.soc.2022.03.011_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040886","article-title":"Unmet medical needs and future perspectives for leiomyosarcoma patients-a position paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)","volume":"13","author":"Kasper","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.soc.2022.03.011_bib82","article-title":"Detection of circulating tumor DNA in patients with uterine leiomyomas","volume":"3","author":"Przybyl","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.soc.2022.03.011_bib83","article-title":"Detection of circulating tumor DNA in patients with leiomyosarcoma with progressive disease","volume":"2019","author":"Hemming","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.soc.2022.03.011_bib84","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-17-3704","article-title":"Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma","volume":"24","author":"Przybyl","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.soc.2022.03.011_bib85","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2020.10.002","article-title":"Homologous recombination repair deficiency as a therapeutic target in sarcoma","volume":"47","author":"Oza","year":"2020","journal-title":"Semin Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:05:56Z","timestamp":1760961956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1055320722000242"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.03.011","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leiomyosarcoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}